Gd-metallofullerenol Nanomaterial As Non-Toxic Breast Cancer Stem Cell-Specific Inhibitor
Ying Liu,Chunying Chen,Pengxu Qian,Xuefei Lu,Baoyun Sun,Xiao Zhang,Liming Wang,Xingfa Gao,Han Li,Zhiyun Chen,Jinglong Tang,Weijie Zhang,Jinquan Dong,Ru Bai,Peter E. Lobie,Qingfa Wu,Suling Liu,Huafeng Zhang,Feng Zhao,Max S. Wicha,Tao Zhu,Yuliang Zhao
DOI: https://doi.org/10.1038/ncomms6988
IF: 6.458
2016-01-01
Nanomedicine Nanotechnology Biology and Medicine
Abstract:The contemporary use of nanomedicines for cancer treatment has been largely limited to serving as carriers for existing therapeutic agents. Here, we provide definitive evidence that, the metallofullerenol nanomaterial Gd@C82(OH)22, while essentially not toxic to normal mammary epithelial cells, possesses intrinsic inhibitory activity against triple-negative breast cancer cells. Gd@C82(OH)22 blocks epithelial-to-mesenchymal transition with resultant efficient elimination of breast cancer stem cells (CSCs) resulting in abrogation of tumour initiation and metastasis. In normoxic conditions, Gd@C82(OH)22 mediates these effects by blocking TGF-β signalling. Moreover, under hypoxic conditions found in the tumour microenvironment, cellular uptake of Gd@C82(OH)22 is facilitated where it functions as a bi-potent inhibitor of HIF-1α and TGF-β activities, enhancing CSC elimination. These studies indicate that nanomaterials can be engineered to directly target CSCs. Thus, Gd-metallofullerenol is identified as a kind of non-toxic CSC specific inhibitors with significant therapeutic potential.